Morgan Stanley Silence Therapeutics PLC Transaction History
Morgan Stanley
- $1.59 Trillion
- Q3 2025
A detailed history of Morgan Stanley transactions in Silence Therapeutics PLC stock. As of the latest transaction made, Morgan Stanley holds 1,207,724 shares of SLN stock, worth $8.3 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,207,724
Previous 1,211,758
0.33%
Holding current value
$8.3 Million
Previous $7.03 Million
10.81%
% of portfolio
0.0%
Previous 0.0%
Shares
25 transactions
Others Institutions Holding SLN
# of Institutions
54Shares Held
20.6MCall Options Held
0Put Options Held
0-
Tcg Crossover Management, LLC Palo Alto, CA3.03MShares$20.8 Million1.76% of portfolio
-
Siren, L.L.C. New York, NY2.91MShares$20 Million0.59% of portfolio
-
Redmile Group, LLC San Francisco, CA2.16MShares$14.9 Million1.24% of portfolio
-
Lombard Odier Asset Management (Usa) Corp New York, NY1.84MShares$12.7 Million0.69% of portfolio
-
Vivo Capital, LLC Palo Alto, CA1.11MShares$7.59 Million0.91% of portfolio
About Silence Therapeutics plc
- Ticker SLN
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,888,400
- Market Cap $247M
- Description
- Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated...